MichaelDerekRothMD
Pulmonology • Los Angeles, CACritical Care Medicine, Pleural Disease
Professor, Medicine, UCLA School of Medicine
Dr. Roth is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
UCLA Medical Center
200 UCLA Medical Plaza, Suite 365B
Los Angeles, CA 90095Phone+1 310-825-8061Fax+1 310-825-8061
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Pulmonary Disease and Critical Care Medicine, 1986 - 1989- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1983 - 1986
David Geffen School of Medicine at UCLAClass of 1983
Certifications & Licensure
CA State Medical License 1984 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate Start of enrollment: 2017 Nov 28
Publications & Presentations
PubMed
- Biological correlates of radiological features of systemic sclerosis interstitial lung disease.Elizabeth R Volkmann, Donald P Tashkin, Mei Leng, Grace Hyun J Kim, Jonathan Goldin
ERJ Open Research. 2025-01-01 - Ventilation and features of the lung environment dynamically alter modeled intrapulmonary aerosol exposure from inhaled electronic cigarettes.Liqiao Li, Haoxuan Chen, Yifang Zhu, Airi Harui, Michael D Roth
Scientific Reports. 2024-12-30 - A Ventilated Three-Dimensional Artificial Lung System for Human Inhalation Exposure Studies.Haoxuan Chen, Airi Harui, Yu Feng, Liqiao Li, Saagar Patel
Environmental Science & Technology. 2024-12-16
Press Mentions
UCLA Receives $6.4 Million to Fund Cannabis ResearchNovember 19th, 2020- Phase 2 Trial of CellCept plus Esbriet for SSc-ILD Enrolling in USAugust 31st, 2020
Antihypertensive Drugs and Risk of COVID-19?March 26th, 2020
Grant Support
- Evaluating Effects Of Marijuana Smoking Ability To Respond To Hepatitis B VaccinNational Center For Research Resources2009–2010
- Pulmonary And Immunologic Effects Of Marijuana Use On HIV And Viral ImmunityNational Institute On Drug Abuse2007–2010
- Cytokines As Predictors Of Disease Progression In Scleroderma Lung DiseaseNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2007–2009
- Cocaine Smoking Effects On The Lung Immunity And Host Defense: HIVNational Center For Research Resources2007
- Vector-Based Generation Of Monoclonal Antibodies Against The CB2 ReceptorNational Institute On Drug Abuse2006–2007
- Pulmonary Effects Of Habitual Use Of MarijuanaNational Institute On Drug Abuse2006
- Effects Of Marijuana On HIV And Viral ImmunityNational Institute On Drug Abuse2006
- Cocaine Smoking Effects On Lung Immunity &Host DefenseNational Institute On Drug Abuse2005–2006
- Adjuvant Immunotherapy For Non-Small Cell Lung CancerNational Cancer Institute2004–2005
- Core--Clinical TrialsNational Cancer Institute2001–2002
- Career Development ProgramNational Cancer Institute2001–2002
- Clinical Centers For Feasibility Studies On Retinoid TREDivision Of Lung Diseases1999–2000
- Cytotoxic Cell Regulation By The Pulmonary MacrophageNational Cancer Institute1990–1992
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
